A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity

Fanghänel, G; Cortinas, L; Sánchez-Reyes, L; Berber, A
February 2000
International Journal of Obesity & Related Metabolic Disorders;Feb2000, Vol. 24 Issue 2, p144
Academic Journal
OBJECTIVE: To evaluate the safety and efficacy of Sibutramine 10 mg per os, once a day in obese patients over a period of 6 months. DESIGN: A monocenter, double-blind, placebo-controlled, parallel, prospective clinical trial. SUBJECTS: 109 male and female obese patients (BMI >30 kg/m²) from 16 to 65 y entered the trial. MEASUREMENTS: Body weight, body mass index (BMI), waist and waist/hip ratio, medical history, assessment of hunger, satiety and diet compliance, standard laboratory assessments, blood pressure, heart rate and ECG. RESULTS: 40 out of 55 patients in the Sibutramine group and 44 out of 54 patients in the placebo group completed the trial. Using the method of last observation carried forward (LOCF), the weight loss in the Sibutramine group was 7.52 kg (95% confidence intervals (95% CI) 6.15; 8.9) and that in the placebo group was 3.56 kg (95% CI 2.41; 4.7). The BMI loss was 3.14 kg/m² (95% CI 2.58; 3.69) in the Sibutramine group and 1.46 kg/m² (95% CI 0.99; 1.93) in the placebo group. The waist reduction was 12.51 cm (95% CI 9.25; 15.77) in the Sibutramine group and 3.26 cm (95% CI 1.38; 5.14) in the placebo group (P<0.05 by paired Student's t-test for all the intragroup comparisons). 32 Sibutramine patients had 45 adverse events, the most frequent adverse events in the Sibutramine group being dry mouth (n=19), increase in blood pressure (n=5), constipation (n=5) and tachycardia (n=5); 23 placebo patients had 29 adverse events, mainly increase in blood pressure (n=11) and dry mouth (n=10). Two Sibutramine patients withdrew from the trial due to adverse events. CONCLUSION: Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function. Sibutramine was well tolerated by most of the patients.


Related Articles

  • New obesity treatment approved. Maudlin, Robert K. // Modern Medicine;Jun99, Vol. 67 Issue 6, p50 

    Reports on the approval of Orlistat (Xenical) for obesity management. Initial body max index of obese patients to whom the therapy is recommended; Findings of the clinical trials on Orlistat-treated subjects; Most commonly observed adverse effects during the first year of therapy.

  • Health Benefits Of Obesity Drug Were Maintained For Two Years.  // RN;May2001, Vol. 64 Issue 5, p114 

    Presents an abstract of the study `Effect of Sibutramine on Weight Maintenance After Weight Loss: A Randomized Trial,' by W.P.T. James, A. Astrup, et al which appeared in the the 2001 issue of the `Lancet.'

  • Comparison of Methods for Delivering a Lifestyle Modification Program for Obese Patients. Digenio, Andres G.; Mancuso, James P.; Gerber, Robert A.; Dvorak, Roman V. // Annals of Internal Medicine;2/17/2009, Vol. 150 Issue 4, p255 

    Background: Physicians frequently prescribe medications for weight loss but offer minimal lifestyle counseling despite the additional benefits of combining both interventions. Objective: To compare 5 methods of delivering a lifestyle modification program to obese patients receiving sibutramine....

  • Cost-utility analysis of a randomized controlled weight loss trial among lactating overweight/obese women. Hagberg, Lars A.; Brekke, Hilde K.; Bertz, Fredrik; Winkvist, Anna // BMC Public Health;2014, Vol. 14 Issue 1, p1 

    Background Overweight and obesity among young, adult women are increasing problems in Sweden as in many other countries. The postpartum period may be a good opportunity to improve eating habits and lose weight in a sustainable manner. The aim was to make a cost-utility analysis of a dietary...

  • What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care? Leiser, Jennifer Paul; Gunning, Karen // Journal of Family Practice;Jun2000, Vol. 49 Issue 6, p572 

    This article discusses research being done on the effectiveness of orlistat in the long-term treatment of obesity in primary care settings, with reference to a study by J. Hauptman, M. A. Klebanoff, J. C. Hauth, et al., which appeared in the 2000 issue of the "Archives of Family Medicine." This...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • DRUGS FOR OBESITY. Mead, Mike // Practice Nurse;9/10/2004, Vol. 28 Issue 4, p64 

    Focuses on prescription drugs available to help obese patients to lose weight. Clinical indications of Sibutramine and Orlistat; Contraindications and side effects of the drugs; Importance of monitoring patients who are taking drug therapy.

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • Immediate Response of Waist Circumference to Sibutramine in High-Risk Diabetic and Non-Diabetic Patients - An Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Finer, Nick; Caterson, Ian; Coutinho, Walmir; Gaal, Luc Van; Maggioni, Aldo; Sharma, Arya M.; Torppedersen, Christian; James, Philip // Diabetes;Jun2007 Supplement 1, Vol. 56, pA691 

    The article presents information on the SCOUT trial that assesses the ability of sibutramine to reduce waist circumference and body weight in obese and overweight patients with and without diabetes at a high risk of a cardiovascular event. A 10 mg of sibutramine with weight management were given...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics